Foghorn Therapeutics (FHTX) Price & Analysis

Compare

396 Followers

FHTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.94 - $10.25

Previous CloseN/A

Volume24.60K

Average Volume (3M)107.01K

Market Cap

$312.61M

Enterprise Value$119.78M

Total Cash (Recent Filing)$199.91M

Total Debt (Recent Filing)$23.70M

Price to Earnings (P/E)―

Beta2.10

Next Earnings

Nov 11, 2025

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding56,529,970

10 Day Avg. Volume90,288

30 Day Avg. Volume107,014

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.38

Enterprise Value/Revenue4.96

Enterprise Value/Gross Profit5.15

Enterprise Value/Ebitda-1.40

Forecast

1Y Price Target

$8.50

Price Target Upside57.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentFHD-909 is gaining traction as a precision medicine targeting SMARCA4-mutated cancers, which includes up to 10% of NSCLC and ~5% of all solid tumors.

Financial Stability$221M cash maintains runway into 2027, providing financial stability for continued development.

PartnershipsFoghorn continues to progress its strategic collaboration with Lilly for FHD-909, which has been the main focus of investor interest in the company.

Bears Say

Financial PerformanceFoghorn reported Q2 collaboration revenues of $7.6M below the $10M estimate.

Revenue PerformanceFoghorn reported Q1 collaboration revenues of $6M, below the $10M estimate.

Foghorn Therapeutics News

Foghorn Therapeutics management to meet virtually with B. Riley

Virtual Meeting to be held on August 12-13 hosted by B. Riley. Published first on TheFly – the...

24d ago

FHTX

Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)

Reports Q2 revenue $7.557M, consensus $7.1M. “We continue to make meaningful progress advancing our pipeline to treat a...

24d ago

FHTX

Buy Rating for Foghorn Therapeutics: Promising Potential of Lead Candidate FHD-909 in Targeting SMARCA4-Mutated Cancers

In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Foghorn Therapeutics,...

22d ago

FHTX

Foghorn Therapeutics Reports Q2 2025 Financial Results

Foghorn Therapeutics, Inc. ( ($FHTX) ) has released its Q2 earnings. Here is a breakdown of the information...

23d ago

FHTX

Foghorn Therapeutics Reports Q2 2025 Financial Update

An announcement from Foghorn Therapeutics ( ($FHTX) ) is now available. On August 5, 2025, Foghorn Therapeutics provided...

24d ago

FHTX

Foghorn Therapeutics Faces Significant Business Risk: Potential Impact on Operations and Investor Confidence

Foghorn Therapeutics, Inc. (FHTX) has disclosed a new risk, in the Regulation category. Foghorn Therapeutics, Inc. faces a...

28d ago

FHTX

Foghorn Therapeutics Signs New Lease Agreement

The latest update is out from Foghorn Therapeutics ( ($FHTX) ). On June 27, 2025, Foghorn Therapeutics Inc....

2M ago

FHTX

Foghorn Therapeutics Holds Successful Annual Meeting

Foghorn Therapeutics ( ($FHTX) ) has provided an announcement. On June 17, 2025, Foghorn Therapeutics Inc. held its...

2M ago

FHTX

Foghorn Therapeutics Reports Q1 2025 Financial Results

Foghorn Therapeutics, Inc. ( ($FHTX) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

FHTX

Promising Advancements and Strategic Collaborations Drive Buy Rating for Foghorn Therapeutics

TD Cowen analyst Yaron Werber has maintained their bullish stance on FHTX stock, giving a Buy rating today....

4M ago

FHTX

Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration

H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on FHTX stock, giving a Buy rating...

4M ago

FHTX

Foghorn Therapeutics Advances FHD-909 Phase 1 Trial

An announcement from Foghorn Therapeutics ( ($FHTX) ) is now available. In May 2025, Foghorn Therapeutics provided a...

4M ago

FHTX

Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)

Reports Q1 revenue $5.9M, consensus $4.97M. “In the first quarter, we continued to progress our novel partnered and...

4M ago

FHTX

Foghorn Therapeutics sees cash runway into 2027

As of March 31, 2025, the Company had $220.6 million in cash, cash equivalents, and marketable securities, providing...

4M ago

FHTX

FHTX FAQ

What was Foghorn Therapeutics’s price range in the past 12 months?

Foghorn Therapeutics lowest stock price was $2.94 and its highest was $10.25 in the past 12 months.

What is Foghorn Therapeutics’s market cap?

Foghorn Therapeutics’s market cap is $312.61M.

When is Foghorn Therapeutics’s upcoming earnings report date?

Foghorn Therapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 74 days.

How were Foghorn Therapeutics’s earnings last quarter?

Foghorn Therapeutics released its earnings results on Aug 05, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.071.

Is Foghorn Therapeutics overvalued?

According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Foghorn Therapeutics pay dividends?

Foghorn Therapeutics does not currently pay dividends.

What is Foghorn Therapeutics’s EPS estimate?

Foghorn Therapeutics’s EPS estimate is -0.33.

How many shares outstanding does Foghorn Therapeutics have?

Foghorn Therapeutics has 56,529,970 shares outstanding.

What happened to Foghorn Therapeutics’s price movement after its last earnings report?

Foghorn Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went down -2.724%.

Which hedge fund is a major shareholder of Foghorn Therapeutics?

Currently, no hedge funds are holding shares in FHTX

Foghorn Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

322.49%

Trailing 12-Months

Asset Growth

-31.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics (FHTX) Earnings & Revenues

Historic Earnings Reports

FHTX Stock 12 Month Forecast

Average Price Target

$8.50

▲(57.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","14":"$14"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5,8,11,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.99,5.6061538461538465,6.222307692307693,6.838461538461539,7.454615384615385,8.070769230769232,8.686923076923076,9.303076923076922,9.919230769230769,10.535384615384615,11.151538461538461,11.767692307692307,12.383846153846154,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.99,5.26,5.53,5.8,6.07,6.34,6.609999999999999,6.88,7.15,7.42,7.6899999999999995,7.96,8.23,{"y":8.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.99,4.913846153846154,4.837692307692308,4.7615384615384615,4.685384615384615,4.609230769230769,4.533076923076923,4.456923076923077,4.380769230769231,4.304615384615385,4.228461538461539,4.1523076923076925,4.076153846153846,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.13,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.86,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >